Identification of ligands by selective amplification of cells transfected with a 5HT2A receptor

• US 7,425,420 B2
• Filed: 03/16/2005
• Issued: 09/16/2008
• Est. Priority Date: 10/07/1999
• Status: Expired due to Fees

• Current Assignee: Acadia Pharmaceuticals Inc.
• Original Assignee: Acadia Pharmaceuticals Inc.
• Inventors: Brann, Mark R.
• Primary Examiner(s): Ulm; John D
• Application Number:
  US11/083,173
• Publication Number:
  US 20050244862A1
• Time in Patent Office: 1,280 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 33/566 using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
• CPC Class Codes: G01N 33/942 Serotonin, i.e. 5-hydroxy-tryptamine

Abstract

The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions. The present invention also relates to a method of identifying compounds which act as inverse agonists of the 5-HT2A receptor, the method comprising contacting a constitutively active 5-HT2A receptor with at least one test compound and determining any decrease in the amount of basal activity of the receptor so as to identify a test compound which is an inverse agonist of the 5-HT2A receptor. Such inverse agonists may be used in the treatment of schizophrenia and related psychoses.

Claims

1. A method of determining whether a substance is a ligand of a constitutively active wild-type 5HT2A receptor, wherein said 5HT2A receptor has a basal response, said method comprising:

obtaining a test cell culture which comprises a first population of cells and a second population of cells, wherein DNA coding for said 5HT2A receptor and also DNA encoding a marker indicative of the extent of cellular proliferation has been introduced into said first population of cells such that the amount of said marker produced by said first population of cells is influenced by the degree to which said 5HT2A receptor is active, and wherein the amount of marker produced by said second population of cells is not influenced by the degree to which said 5HT2A receptor is active or wherein said second population of cells does not comprise DNA coding for said marker;

contacting said test cell culture with a test substance which is a potential ligand of said 5HT2A receptor;

obtaining a control cell culture, said control cell culture comprising cells comprising said DNA coding for said 5HT2A receptor and said DNA coding for said marker, wherein said control cell culture has not been contacted with said test substance;

determining whether the extent of proliferation of said first population of cells in said test cell culture is significantly greater or significantly less than the extent of proliferation of said cells in said control cell culture by comparing the amount of marker activity produced by said first population of cells in said test culture to the amount of marker activity produced by said cells in said control culture, wherein said test substance is an agonist of said 5HT2A receptor if the extent of proliferation of said first population of cells in said test culture is significantly greater than the extent of proliferation of said cells in said control culture and wherein said test substance is an antagonist or inverse agonist of said 5HT2A receptor if the extent of proliferation of said first population of cells in said test culture is significantly less than the extent of proliferation of said cells in said control culture.

2. The method of claim 1, wherein said determining step is performed by measuring the amount of said marker produced by said test culture at a time after contacting said test cell culture with said test substance which is prior to the time at which foci resulting from the proliferation of said first population of cells would be visible and by measuring the amount of said marker produced by said control cell culture at the same time as the amount of said marker in said test culture was measured.

3. The method of claim 1, wherein said determining step is performed within two weeks of the day that said test cell culture was contacted with said substance.

4. The method of claim 1, wherein said determining step is performed within 4 days of the day that said test cell culture was contacted with said substance.

5. The method of claim 1, further comprising contacting said test cell culture and said control cell culture with a substance known to be an agonist of said 5HT2A receptor.

6. The method of claim 1, further comprising contacting said test cell culture and said cell control culture with a substance known to be an antagonist of said 5HT2A receptor.

7. The method of claim 1, wherein said test cell culture and said control cell culture are obtained by introducing said DNA coding for said 5HT2A receptor and said DNA coding for said marker into a starting cell culture and dividing said starting cell culture into multiple aliquots.

8. The method of claim 1, wherein said determining step comprises determining whether said substance inhibits said basal receptor response, wherein said substance is an inverse agonist of said 5HT2A receptor if said substance inhibits said basal receptor response of said 5HT2A receptor.

9. The method of claim 1, wherein said second population of cells comprises cells selected from the group consisting of:

(a) cells which do not comprise DNA coding for said marker;

(b) cells which do not comprise DNA coding for said 5HT2A receptor;

(c) cells which comprise DNA coding for said 5HT2A receptor but not DNA coding for said marker;

(d) cells which comprise DNA coding for said marker but not DNA coding for said 5HT2A receptor; and

(e) a combination of two or more of the cells recited in (a)-(d).

10. The method of claim 1, wherein said method is a high throughput screening assay.

11. The method of claim 1, wherein said method comprises determining whether said test compound is an inverse agonist of said 5HT2A receptor.

12. The method of claim 1, wherein DNA coding for an α

subunit of a Gq protein has been introduced into said first population of cells and into said control culture.

13. A method of determining whether a substance is a ligand of a constitutively active wild-type 5HT2A receptor, wherein said 5HT2A receptor has a basal response, said method comprising,

obtaining a test cell culture which comprises a first population of cells and a second population of cells, wherein DNA coding for said 5HT2A receptor and also DNA encoding a marker indicative of the extent of cellular proliferation has been introduced into said first population of cells such that the amount of said marker produced by said first population of cells is influenced by the degree to which said 5HT2A receptor is active, and wherein the amount of said marker produced by said second population of cells is not influenced by the degree to which said 5HT2A receptor is active or wherein said second population of cells does not comprise DNA coding for said marker;

contacting said test cell culture with a test substance which is a potential ligand of said 5HT2A receptor; and

determining whether the test substance confers a competitive advantage or a competitive disadvantage on the cells in said first population of said test culture relative to the cells in said second population of said test culture by measuring the amount of said marker produced by said test culture.

14. The method of claim 13, wherein said determining step is performed by measuring the amount of said marker produced by said test culture at a time after contacting said test cell culture with said test substance which is prior to the time at which foci resulting from the proliferation of said first population of cells would be visible.

15. The method of claim 13, wherein said determining step is performed within two weeks of the day that said test cell culture was contacted with said substance.

16. The method of claim 13, wherein said determining step is performed within 4 days of the day that said test cell culture was contacted with said substance.

17. The method of claim 13, further comprising contacting said test cell culture with a substance known to be an agonist of said 5HT2A receptor.

18. The method of claim 13, further comprising contacting said test cell culture with a substance known to be an antagonist of said 5HT2A receptor.

19. The method of claim 13, wherein said determining step comprises determining whether said substance inhibits said basal receptor response, wherein said substance is an inverse agonist of said 5HT2A receptor if said substance inhibits said basal receptor response of said 5HT2A receptor.

20. The method of claim 13, wherein said second population of cells comprises cells selected from the group consisting of

(a) cells which do not comprise DNA coding for said marker;

(b) cells which,do not comprise DNA coding for said 5HT2A receptor;

(c) cells which comprise DNA coding for said receptor but not DNA coding for said marker;

(d) cells which comprise DNA coding for said marker but not DNA coding for said 5HT2A receptor; and

(e) a combination of two or more of the cells recited in (a)-(d).

21. The method of claim 13, wherein said method is a high throughput screening assay.

22. The method of claim 13, wherein said method comprises determining whether said test compound is an inverse agonist of said 5HT2A receptor.

23. The method of claim 13, wherein DNA coding for an α

subunit of a Gq protein has been introduced into said first population of cells.

24. The method of claim 13, wherein 5-50 ng of DNA coding for said 5HT2A receptor has been introduced into said first population of cells.

25. A method of determining whether a substance is a ligand of a constitutively active wild-type 5HT2A receptor, wherein said 5HT2A receptor has a basal receptor response, said method comprising:

obtaining a test cell culture which comprises a first population of cells and a second population of cells, wherein DNA coding for said 5HT2A receptor and also DNA encoding a marker indicative of the extent of cellular proliferation has been introduced into said first population of cells such that the amount of said marker produced by said first population of cells is influenced by the degree to which said 5HT2A receptor is active, wherein the transcription of said DNA coding for said marker is not under the control of said 5HT2A receptor, and wherein the amount of marker in said second population of cells is not influenced by the degree to which said 5HT2A receptor is active or wherein said second population of cells does not comprise said DNA coding for said marker;

contacting said test cell culture with a test substance which is a potential ligand of said 5HT2A receptor;

obtaining a control cell culture, said control cell culture comprising cells comprising said DNA coding for said 5HT2A receptor and said DNA coding for said marker, wherein said control cell culture has not been contacted with said test substance;

determining whether the extent of proliferation of said first population of cells in said test cell culture is significantly greater or significantly less than the extent of proliferation of said cells in said control cell culture by comparing the amount of marker activity produced by said first population of cells in said test culture to the amount of marker activity produced by said cells in said control culture, wherein said test substance is an agonist of said 5HT2A receptor if the extent of proliferation of said first population of cells in said test culture is significantly greater than the extent of proliferation of said cells in said control culture and wherein said test substance is an antagonist or inverse agonist of said 5HT2A receptor if the extent of proliferation of said first population of cells in said test culture is significantly less than the extent of proliferation of said cells in said control culture.

26. The method of claim 25, wherein said determining step comprises determining whether said substance inhibits said basal receptor response, wherein said substance is an inverse agonist of said 5HT2A receptor if said substance inhibits said basal receptor response of said 5HT2A receptor.

27. The method of claim 25, wherein said second population of cells comprises cells selected from the group consisting of:

(a) cells which do not comprise DNA coding for said marker;

(b) cells which do not comprise DNA coding for said 5HT2A receptor;

(c) cells which comprise DNA coding for said receptor but not DNA coding for said marker;

(d) cells which comprise DNA coding for said marker but not DNA coding for said 5HT2A receptor; and

(e) a combination of two or more of the cells recited in (a)-(d).

28. The method of claim 25, wherein said method is a high throughput screening assay.

29. The method of claim 25, wherein said method comprises determining whether said test compound is an inverse agonist of said 5HT2A receptor.

30. The method of claim 25, wherein DNA coding for an α

subunit of a Gq protein has been introduced into said first population of cells and into said control culture.

31. The method of claim 25, wherein 5-50 ng of DNA coding for said 5HT2A receptor has been introduced into said first population of cells.

32. A method of determining whether a substance is a ligand of a constitutively active wild-type 5HT2A receptor, wherein said 5HT2A receptor has a basal response, said method comprising:

obtaining a test cell culture which comprises a first population of cells and a second population of cells, wherein DNA coding for a plurality of receptors and also DNA encoding a marker indicative of the extent of cellular proliferation has been introduced into said first population of cells such that the amount of said marker produced by said first population of cells is influenced by the degree to which said plurality of receptors are active, and wherein the amount of said marker produced by said second population of cells is not influenced by the degree to which said plurality of receptors are active or wherein said second population of cells does not comprise said DNA coding for said marker, wherein at least one of said plurality of receptors is a constitutively active wild-type 5HT2A receptor, wherein said 5HT2A receptor has a basal or constitutive receptor response;

contacting said test cell culture with a test substance which is a potential ligand of said 5HT2A receptor;

obtaining a control cell culture, said control cell culture comprising cells comprising said DNA coding for said plurality of receptors and said DNA coding for said marker, wherein said control cell culture has not been contacted with said test substance and wherein at least one of said plurality of receptors is a constitutive active wild type 5HT2A receptor;

determining whether the extent of proliferation of cells in said first population of cells in said test cell culture is significantly greater or significantly less than the extent of proliferation of said cells in said control cell culture by comparing the amount of marker activity produced by said first population of cells in said test culture to the amount of marker activity produced by said cells in said control culture, wherein said test substance is an agonist of said 5HT2A receptor if the extent of proliferation of cells in said first population of cells in said test culture which comprise DNA coding for said 5HT2A receptor is significantly greater than the extent of proliferation of said cells in said control culture which comprise DNA coding for said 5HT2A receptor and wherein said test substance is an antagonist or inverse agonist of said 5HT2A receptor if the extent of proliferation of cells in said first population of cells in said test culture which comprise DNA coding for said 5HT2A receptor is significantly less than the extent of proliferation of cells in said control culture which comprise DNA coding for said 5HT2A receptor.

33. The method of claim 32, wherein DNA encoding a plurality of markers has been introduced into said cells comprising said DNA coding for said plurality of receptors such that cells comprising DNA encoding a given receptor comprise DNA encoding a different marker than cells comprising DNA encoding the other receptors.

34. The method of claim 32, wherein said determining step is performed by measuring the amount of said marker produced by said test culture at a time after contacting said test cell culture with said test substance which is prior to the time at which foci resulting from the proliferation of said first population of cells would be visible and by measuring the amount of said marker produced by said control cell culture at the same time as the amount of said marker in said test culture was measured.

35. The method of claim 32, wherein said determining step is performed within two weeks of the day that said test cell culture was contacted with said substance.

36. The method of claim 32, wherein said determining step is performed within 4 days of the day that said test cell culture was contacted with said substance.

37. The method of claim 32, further comprising contacting said test cell culture and said control cell culture with a substance known to be an agonist of said 5HT2A receptor.

38. The method of claim 32, further comprising contacting said test cell culture and said cell control culture with a substance known to be an antagonist of said 5HT2A receptor.

39. The method of claim 32, wherein said test cell culture and said control cell culture are obtained by introducing DNA coding for said plurality of receptors and DNA coding for said marker into a starting cell culture and dividing said starting cell culture into multiple aliquots.

40. The method of claim 32, wherein said determining step comprises determining whether said substance inhibits said basal receptor response of said 5HT2A receptor, wherein said substance is an inverse agonist of said 5HT2A receptor if said substance inhibits said basal receptor response of said 5HT2A receptor.

41. The method of claim 32, wherein said second population of cells comprises cells selected from the group consisting of:

(a) cells which do not comprise DNA coding for said marker;

(b) cells which do not comprise DNA encoding any of said plurality of receptors;

(c) cells which comprise DNA encoding at least one of said plurality of receptors but not DNA coding for said marker;

(d) cells which comprise DNA coding for said marker but not DNA encoding any of said plurality of receptors; and

(e) a combination of two or more of the cells recited in (a)-(d).

42. The method of claim 32, wherein said method is a high throughput screening assay.

43. The method of claim 32, wherein said method comprises determining whether said test compound is an inverse agonist of said 5HT2A receptor.

44. The method of claim 32, wherein DNA coding for an α

subunit of a Gq protein has been introduced into said first population of cells and into said control culture.

45. The method of claim 32, wherein 5-50 ng of DNA coding for said 5HT2A receptor has been introduced into said first population of cells.

46. A method of determining whether a substance is a ligand of a constitutively active wild-type 5HT2A receptor, wherein said 5HT2A receptor has a basal response, said method comprising,

obtaining a test cell culture which comprises a first population of cells and a second population of cells, wherein DNA coding for a plurality of receptors and also DNA encoding a marker indicative of the extent of cellular proliferation has been introduced into said first population of cells such that the amount of said marker produced by said first population of cells is influenced by the degree to which said plurality of receptors are active, and wherein the amount of said marker in said second population of cells is not influenced by the degree to which said plurality of receptors are active or wherein said second population of cells does not comprise said DNA coding for said marker wherein at least one of said plurality of receptors is a constitutively active wild-type 5HT2A receptor, wherein said 5HT2A receptor has a basal response;

contacting said test cell culture with a test substance which is a potential ligand of said 5HT2A receptor; and

determining whether the test substance confers a competitive advantage or a competitive disadvantage on cells in said first population of said test culture which express said 5HT2A receptor relative to the cells in said second population of said test culture which comprise said 5HT2A receptor by measuring the amount of said marker produced by said test culture.

47. The method of claim 46, wherein DNA encoding a plurality of markers has been introduced into said cells comprising said DNA coding for said plurality of receptors such that cells comprising DNA encoding a given receptor comprise DNA encoding a different marker than cells comprising DNA encoding the other receptors.

48. The method of claim 46, wherein said determining step is performed by measuring the amount of said marker produced by said test culture at a time after contacting said test cell culture with said test substance which is prior to the time at which foci resulting from the proliferation of said first population of cells would be visible.

49. The method of claim 46, wherein said determining step is performed within two weeks of the day that said test cell culture was contacted with said substance.

50. The method of claim 46, wherein said determining step is performed within 4 days of the day that said test cell culture was contacted with said substance.

51. The method of claim 46, further comprising contacting said test cell culture with a substance known to be an agonist of said 5HT2A receptor.

52. The method of claim 46, further comprising contacting said test cell culture with a substance known to be an antagonist of said 5HT2A receptor.

53. The method of claim 46, wherein said determining step comprises determining whether said substance inhibits said basal receptor response of said 5HT2A receptor wherein said substance is an inverse agonist of said 5HT2A receptor if said substance inhibits said basal receptor response of said 5HT2A receptor.

54. The method of claim 46, wherein said second population of cells comprises cells selected from the group consisting of:

(a) cells which do not comprise DNA coding for said marker;

(b) cells which do not comprise DNA encoding any of said plurality of receptors;

(c) cells which comprise DNA encoding at least one of said plurality of receptors but not DNA coding for said marker;

(d) cells which comprise DNA coding for said marker but not DNA encoding any of said plurality of receptors; and

(e) a combination of two or more of the cells recited in (a)-(d).

55. The method of claim 46, wherein said method is a high throughput screening assay.

56. The method of claim 46, wherein said method comprises determining whether said test compound is an inverse agonist of said 5HT2A receptor.

57. The method of claim 46, wherein DNA coding for an α

subunit of a Gq protein has been introduced into said first population of cells.

58. The method of claim 46, wherein 5-50 ng of DNA coding for said 5HT2A receptor has been introduced into said first population of cells.

59. A method of determining whether a substance is a ligand of a constitutively active wild-type 5HT2A receptor, wherein said 5HT2A receptor has a basal response, said method comprising:

obtaining a test cell culture which comprises a first population of cells and a second population of cells, wherein DNA coding for a plurality of receptors and also DNA encoding a marker indicative of the extent of cellular proliferation has been introduced into said first population of cells such that the amount of said marker produced by said first population of cells is influenced by the degree to which said plurality of receptors are active, wherein the transcription of said DNA coding for said marker is not under the control of any of said plurality of receptors, and wherein the amount of said marker produced by said second population of cells is not influenced by the degree to which said plurality of receptors are active or wherein said second population of cells does not comprise said DNA coding for said marker, wherein at least one of said plurality of receptors is a 5HT2A receptor;

contacting said test cell culture with a test substance which is a potential ligand of said 5HT2A receptor;

obtaining a control cell culture, said control cell culture comprising cells comprising said DNA coding for said plurality of receptors and said DNA coding for said marker, wherein said control cell culture has not been contacted with said test substance and wherein at least one of said plurality of receptors is a constitutively active wild type 5HT2A receptor;

determining whether the extent of proliferation of said first population of cells in said test cell culture is significantly greater or significantly less than the extent of proliferation of said cells in said control cell culture by comparing the amount of marker activity produced by said first population of cells in said test culture which comprise DNA coding for said 5HT2A receptor to the amount of marker activity produced by said cells in said control culture which comprise DNA coding for said 5HT2A receptor, wherein said test substance is an agonist of said 5HT2A receptor if the extent of proliferation of said first population of cells in said test culture which comprise DNA coding for said 5HT2A receptor is significantly greater than the extent of proliferation of said cells in said control culture which comprise DNA coding for said 5HT2A receptor and wherein said test substance is an antagonist or inverse agonist of said 5HT2A receptor if the extent of proliferation of said first population of cells in said test culture which comprise DNA coding for said 5HT2A receptor is significantly less than the extent of proliferation of said cells in said control culture which comprise DNA coding for said 5HT2A receptor.

60. The method of claim 59, wherein said determining step comprises determining whether said substance inhibits said basal receptor response of said 5HT2A receptor, wherein said substance is an inverse agonist of said 5HT2A receptor if said substance inhibits said basal receptor response of said 5HT2A receptor.

61. The method of claim 59, wherein said second population of cells comprises cells selected from the group consisting of:

(a) cells which do not comprise DNA coding for said marker;

(b) cells which do not comprise DNA encoding any of said plurality of receptors;

(c) cells which comprise DNA encoding at least one of said plurality of receptors but not DNA coding for said marker;

(d) cells which comprise DNA coding for said marker but not DNA encoding any of said plurality of receptors; and

(e) a combination of two or more of the cells recited in (a)-(d).

62. The method of claim 59, wherein said method is a high throughput screening assay.

63. The method of claim 59, wherein said method comprises determining whether said test compound is an inverse agonist of said 5HT2A receptor.

64. The method of claim 59, wherein DNA coding for an α

subunit of a Gq protein has been introduced into said first population of cells and into said control culture.

65. The method of claim 59, wherein 5-50 ng of DNA coding for said 5HT2A receptor has been introduced into said first population of cells.